Dalton Heidi J, Reeder Ron, Garcia-Filion Pamela, Holubkov Richard, Berg Robert A, Zuppa Athena, Moler Frank W, Shanley Thomas, Pollack Murray M, Newth Christopher, Berger John, Wessel David, Carcillo Joseph, Bell Michael, Heidemann Sabrina, Meert Kathleen L, Harrison Richard, Doctor Allan, Tamburro Robert F, Dean J Michael, Jenkins Tammara, Nicholson Carol
1 Department of Child Health, Phoenix Children's Hospital, Phoenix, Arizona.
2 Department of Pediatrics, University of Utah, Salt Lake City, Utah.
Am J Respir Crit Care Med. 2017 Sep 15;196(6):762-771. doi: 10.1164/rccm.201609-1945OC.
Extracorporeal membrane oxygenation (ECMO) is used for respiratory and cardiac failure in children but is complicated by bleeding and thrombosis.
(1) To measure the incidence of bleeding (blood loss requiring transfusion or intracranial hemorrhage) and thrombosis during ECMO support; (2) to identify factors associated with these complications; and (3) to determine the impact of these complications on patient outcome.
This was a prospective, observational cohort study in pediatric, cardiac, and neonatal intensive care units in eight hospitals, carried out from December 2012 to September 2014.
ECMO was used on 514 consecutive patients under age 19 years. Demographics, anticoagulation practices, severity of illness, circuitry components, bleeding, thrombotic events, and outcome were recorded. Survival was 54.9%. Bleeding occurred in 70.2%, including intracranial hemorrhage in 16%, and was independently associated with higher daily risk of mortality. Circuit component changes were required in 31.1%, and patient-related clots occurred in 12.8%. Laboratory sampling contributed to transfusion requirement in 56.6%, and was the sole reason for at least one transfusion in 42.2% of patients. Pump type was not associated with bleeding, thrombosis, hemolysis, or mortality. Hemolysis was predictive of subsequent thrombotic events. Neither hemolysis nor thrombotic events increased the risk of mortality.
The incidences of bleeding and thrombosis are high during ECMO support. Laboratory sampling is a major contributor to transfusion during ECMO. Strategies to reduce the daily risk of bleeding and thrombosis, and different thresholds for transfusion, may be appropriate subjects of future trials to improve outcomes of children requiring this supportive therapy.
体外膜肺氧合(ECMO)用于治疗儿童呼吸和心力衰竭,但会并发出血和血栓形成。
(1)测量ECMO支持期间出血(需要输血的失血或颅内出血)和血栓形成的发生率;(2)确定与这些并发症相关的因素;(3)确定这些并发症对患者预后的影响。
这是一项前瞻性观察队列研究,于2012年12月至2014年9月在八家医院的儿科、心脏科和新生儿重症监护病房进行。
对514例19岁以下连续患者使用了ECMO。记录人口统计学资料、抗凝措施、疾病严重程度、循环系统组件、出血情况、血栓形成事件及预后。生存率为54.9%。70.2%的患者发生出血,其中16%发生颅内出血,出血与每日较高的死亡风险独立相关。31.1%的患者需要更换循环系统组件,12.8%的患者发生与患者相关的血栓。实验室采样导致56.6%的患者需要输血,并且是42.2%的患者至少一次输血的唯一原因。泵的类型与出血、血栓形成、溶血或死亡率无关。溶血可预测随后的血栓形成事件。溶血和血栓形成事件均未增加死亡风险。
ECMO支持期间出血和血栓形成的发生率很高。实验室采样是ECMO期间输血的主要原因。降低每日出血和血栓形成风险的策略以及不同的输血阈值,可能是未来试验中改善需要这种支持性治疗的儿童预后的合适研究对象。